DUBLIN--(BUSINESS WIRE)--The "Biosimilar Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
This report on the global biosimilar market provides qualitative and quantitative analysis for the period from 2018 to 2026.
The report predicts the global biosimilar market to grow with a CAGR of 35.12% over the forecast period from 2020-2026. The study on biosimilar market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026.
The report on biosimilar market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biosimilar market over the period of 2018 to 2026. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biosimilar market over the period of 2018 to 2026. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
What does this Report Deliver?
- Comprehensive analysis of the global as well as regional markets of the biosimilar market.
- Complete coverage of all the segments in the biosimilar market to analyze the trends, developments in the global market and forecast of market size up to 2026.
- Comprehensive analysis of the companies operating in the global biosimilar market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Market Dynamics
Drivers
- Growing number of geriatric population and increasing awareness about biosimilar among the patients and doctors
- Increasing number of patients with chronic illnesses such as diabetes and cancer
Restraints
- The high manufacturing cost and complexity of production are expected to be the major restraints
Opportunities
- The expiry of patents of various blockbuster drugs is a major factor for the growth
Companies Profiled
- Allergan plc
- BIOCAD
- Biocon Limited
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Celltrion Inc
- Coherus BioSciences, Inc
- Dr. Reddy's Laboratories Ltd
- Genor BioPharma Co. Ltd
- Novartis AG
For more information about this report visit https://www.researchandmarkets.com/r/codcdn
